Posts Tagged ‘diabetes treatment’

Trends in Diabetes, Obesity, and Equitable Access to GLP-1s

July 29, 2024 — When the subject of equitable access to GLP-1s arises, contrasting perspectives of what is equitable become apparent. Last week in the Annals of Internal Medicine, an analysis of prescription data for GLP-1 agonists made two facts about their use very clear. First, their use for obesity is growing much faster than the use for type […]

Putting the Best Meds Within Reach for Everyone

September 9, 2022 — Be careful what you wish for, says the wisdom of the ages. It’s all about unintended consequences. Right now, policymakers all over the political spectrum are wishing to solve the problem of drug pricing in the U.S. The simple fact is that drug pricing in the U.S. puts the best, most innovative drugs out of […]

FDA Approves “An Important Advance,” Tirzepatide

May 14, 2022 — Yesterday, FDA approved tirzepatide for type 2 diabetes, calling it “an important advance.” The brand name will be Mounjaro. This is the same drug for which its maker, Eli Lilly and Company, announced remarkable results in a phase 3 obesity study barely two weeks ago. It is the first of its kind – a dual […]

Losing Ground on Diabetes Control

June 12, 2021 — Would it be too strong to call this one of the biggest public health failures of the 21st century? We ask this about diabetes control because it appears to be out of control. After a decade of better control at the turn of the century, key markers of health in people living with diabetes have […]

A Green Light from FDA for Oral Semaglutide

September 21, 2019 — Holy grail? Game-changer? These superlatives were flying around as FDA approved Rybelsus – oral semaglutide – yesterday for type 2 diabetes. We don’t know about all that puffery, but it’s clear enough that this approval is a big deal. Oral semaglutide will be the first ever GLP-1 agonist in a pill. Up until now, taking […]

PIONEER Studies Converge at the ADA Meeting

June 9, 2019 — Some of the most discussed news coming from the American Diabetes Association Scientific Sessions in San Francisco is all about the PIONEER studies of oral semaglutide. This drug is presently under review at FDA for type 2 diabetes. Interest is keen because it will be the first of its class that doesn’t require an injection. […]